PCM
GENE

Prelude Capital Management’s Genetic Technologies Ltd. GENE Stock Holding History

Prelude Capital Management’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5
Closed – – 1841
2016
Q4 		$0 Sell
5
-10
-67% -$277 ﹤0.01% 1837
2016
Q3 		$1K Buy
+15
New +$611 ﹤0.01% 1550

Other funds holding GENE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's GENE Position: Q1 2017 in Review

Prelude Capital Management sold out of Genetic Technologies Ltd. (GENE) in Q1 2017, closing a stake of 5 shares.

Prelude Capital Management first reported a position in GENE in Q3 2016 and held it in 2 quarters. The position peaked at $1K in Q3 2016. 13 funds tracked by Wall St. Rank hold GENE as of Q1 2017.

  • Prelude Capital Management reported no remaining Genetic Technologies Ltd. position as of Q1 2017 after selling out during the quarter.
  • Prelude Capital Management sold 5 Genetic Technologies Ltd. shares in Q1 2017.
  • Prelude Capital Management first reported a position in Genetic Technologies Ltd. in Q3 2016 and held it in 2 quarters.
  • Prelude Capital Management's Genetic Technologies Ltd. position peaked at $1K in Q3 2016.
  • 13 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q1 2017.

Based on Prelude Capital Management's 13F filing for Q1 2017, filed 15 May 2017.